Skip to main content
SpringerLink
Log in

A phase II trial of piroxantrone in adenocarcinoma of the pancreas

A Southwest Oncology Group Study

  • Phase II Clinical Trials
  • Brief Report
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Thirty-five evaluable patients with advanced adenocarcinoma of the pancreas were treated with piroxantrone at a dose of 150 mg/m2 intravenously every 21 days. No objective responses were observed (95% confidence interval 0% –10%). Toxicities of grade ≥ 3 were primarily hematologic and were seen in 28 patients. Piroxantrone is inactive in pancreatic cancer and no further investigation of this agent in this tumor is recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Boring CC, Squires TS, Tong T: Cancer Statistics, 1991. Ca 41:19–36, 1991

    PubMed  Google Scholar 

  2. Brennan MF, Kinsella TJ, Friedman M: Cancer of the Pancreas.In DeVita VT, Hellman S, Rosenberg SA: Cancer Principles and Practice of Oncology, pp. 800–835. Philadelphia, JB Lippincott, third edition, 1989

    Google Scholar 

  3. Showalter HD, Johnson JL, Werbel LM, Leopold WR, Jackson RC, Elslager EF: 5-[(aminoalkyl)amino] substituted anthra[1,9-cd]pyrazol-6(2h)-ones as novel anticancer agents. Synthesis and biological evaluations. J Med Chem 27:253–255, 1984

    PubMed  Google Scholar 

  4. Leopold WR, Nelson JM, Plowman J, Jackson RC: Anthrapyrazoles, a new class of intercalating agents against murine tumors. Cancer Res 45:5532–5539, 1985

    PubMed  Google Scholar 

  5. Burchenal J, Pancoast T, Elslayer E: Anthrapyrazole and amsacrine analogues in mouse and human leukemiain vitro andin vivo. Proc Am Assoc Cancer Res 26:339, 1985

    Google Scholar 

  6. Hantel A, Donehower RC, Rowinsky EK, Vance E, Clarke BV, McGuire WP, Ettinger DS, Noe DA, Grochow LB: Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole. Cancer Res 50:3284–3288, 1990

    PubMed  Google Scholar 

  7. Miller A, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Brooke Army Medical Center, San Antonio, TX

    Terry R. Jenkins

  2. Southwest Oncology Group Statistical Center, Seattle, WA

    Catherine Tangen

  3. Temple University, Philadelphia, PA

    John S. Macdonald

  4. University of Texas Health Science Center, San Antonio, TX

    Geoffrey Weiss

  5. Henry Ford Hospital, Detroit, MI

    Robert Chapman

  6. Loyola University Stritch School of Medicine, Maywood, IL, USA

    Alexander Hantel

Authors
  1. Terry R. Jenkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catherine Tangen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John S. Macdonald
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Geoffrey Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert Chapman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alexander Hantel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jenkins, T.R., Tangen, C., Macdonald, J.S. et al. A phase II trial of piroxantrone in adenocarcinoma of the pancreas. Invest New Drugs 11, 329–331 (1993). https://doi.org/10.1007/BF00874432

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00874432

Key words

Search

Navigation